What are the responsibilities and job description for the Director, New Product Commercialization position at Alnylam?
Overview
The Director New Product Commercialization, Zilebesiran is a pivotal role that will support all commercial activities related to the successful commercialization of Zilebesiran, Alnylam's flagship development program in hypertension. There has been little innovation in the management of hypertension in decades, and Zilebesiran has the potential to fundamentally reshape the existing treatment paradigm. This role will be central to defining how to introduce this potentially ground-breaking therapy to market, will be a core member of the Zilebesiran Early Commercial & Medical Strategy Team, and will report to the Global commercial lead.
This position is onsite / hybrid onsite and will be primarily located in Cambridge, MA.
Key Responsibilities
- Collaborate with the Early Commercial & Medical Strategy Team to analyze and communicate insights on the evolving hypertension treatment landscape, patient needs and competitive dynamics across major markets (US, EU, Japan),
- Support development and execution of a strategy to maximize Zilbesiran's market potential, including life cycle management and short, medium- and long-term commercialization plans
- Liaise extensively with internal and external experts to identify and assess potential opportunities / risks for Zilebesiran, and translate key insights from scientific experts (internal R&D colleagues external opinion leaders) into clear, actionable strategies.
- Collaborate closely with R&D leadership, cross-functional Program Team members, finance, and regional stakeholders in optimizing planning and decision-making (including long-range forecasting and valuation / prioritization) for Zilebesiran.
- Serve as the lead for the commercialization functions on the Early Commercial & Medical Strategy Team (including Access and Medical Affairs) and be the central integrator of information, insights, and perspectives related to commercialization from global and regional stakeholders.
- Maintain high level of competitive intelligence within the cardiovascular market.
Qualifications
About Alnylam : Alnylam Pharmaceuticals (Nasdaq : ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture : Our people-first culture is guided by our core values : fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
